Nalls Sherbakoff Group’s Pharming Group PHAR Stock Holding History

Nalls Sherbakoff Group’s Portfolio PHAR Stock Details PHAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$15.4K	Hold	870	–	–	0.01%	297
2025 Q3	$12.6K	Hold	870	–	–	0.01%	312
2025 Q2	$9.3K	Hold	870	–	–	0.01%	331
2025 Q1	$7.28K	Buy	+870	New	+$7.8K	0.01%	312

Other funds holding PHAR

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $240M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nalls Sherbakoff Group's PHAR Position: Q4 2025 in Review

Nalls Sherbakoff Group held its Pharming Group (PHAR) position steady in Q4 2025 at 870 shares worth $15.4K. The position accounts for 0.01% of the portfolio, ranked #297.

Nalls Sherbakoff Group first reported a position in PHAR in Q1 2025 and has held it in 4 quarters since. 11 funds tracked by Wall St. Rank hold PHAR as of Q4 2025.

Nalls Sherbakoff Group held 870 shares of Pharming Group worth $15.4K as of Q4 2025.
Nalls Sherbakoff Group left its Pharming Group share count unchanged in Q4 2025.
Pharming Group made up 0.01% of Nalls Sherbakoff Group's portfolio in Q4 2025, its #297 holding.
Nalls Sherbakoff Group first reported a position in Pharming Group in Q1 2025 and has held it in 4 quarters since.
11 funds tracked by Wall St. Rank held Pharming Group as of Q4 2025.

Based on Nalls Sherbakoff Group's 13F filing for Q4 2025, filed 12 Mar 2026.